"Virginiamycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclic polypeptide antibiotic complex from Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others. It consists of 2 major components, VIRGINIAMYCIN FACTOR M1 and virginiamycin Factor S1. It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry.
| Descriptor ID |
D014769
|
| MeSH Number(s) |
D04.345.566.802.875 D12.644.641.802.875
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Virginiamycin".
Below are MeSH descriptors whose meaning is more specific than "Virginiamycin".
This graph shows the total number of publications written about "Virginiamycin" by people in this website by year, and whether "Virginiamycin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 3 | 0 | 3 |
| 2004 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Virginiamycin" by people in Profiles.
-
Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin. Antimicrob Agents Chemother. 2004 Sep; 48(9):3583-5.
-
Relationship between myalgias/arthralgias occurring in patients receiving quinupristin/dalfopristin and biliary dysfunction. J Antimicrob Chemother. 2004 Jun; 53(6):1105-8.
-
Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother. 2004 Apr; 53(4):646-9.
-
Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline. Antimicrob Agents Chemother. 2001 Nov; 45(11):3202-4.
-
Cerebrospinal fluid concentrations of quinupristin-dalfopristin in a patient with vancomycin-resistant Enterococcus faecium [correction of faecalis] ventriculitis. Pharmacotherapy. 2001 Jun; 21(6):748-50.
-
New antibiotics for infections caused by resistant organisms. Support Care Cancer. 2001 Jan; 9(1):8-10.
-
Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci. Antimicrob Agents Chemother. 2000 Jul; 44(7):1838-41.
-
Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. Eur J Clin Microbiol Infect Dis. 1999 Mar; 18(3):199-202.